This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Colozza, M. Articles by Cardoso, F. Search for Related Content PubMed PubMed Citation Articles by Colozza, M. Articles by Cardoso, F.

Breast Cancer

Achievements in Systemic Therapies in the Pregenomic Era in Metastatic Breast Cancer

^aS.C. Oncologia Medica, Azienda Ospedaliera, Perugia, Italy; ^bMedical Oncology Clinic, Jules Bordet Institute, Brussels, Belgium

Key Words. Metastatic breast cancer • Chemotherapy • Endocrine therapy • Trastuzumab • Taxanes

Correspondence: Fatima Cardoso, M.D., Jules Bordet Institute, Boulevard de Waterloo, 125, 1000 Brussels, Belgium. Telephone: 32-2-541-3082; Fax: 32-2-538-0858; e-mail: fatima.cardoso{at}bordet.be

Over the last decades, the introduction of several new agents into clinical practice has significantly improved disease control and obtained some, albeit rare, survival benefits in metastatic breast cancer (MBC). Despite these results, the choice of treatment for the majority of patients is still empirically based, since the only two predictive factors with level 1 evidence for clinical use are hormonal receptor status for endocrine therapy and HER-2 status for trastuzumab therapy.

Important improvements in the endocrine therapy of both pre- and postmenopausal women with hormone-responsive disease have been achieved. For premenopausal women, ovarian function suppression with luteinizing hormone-releasing hormone analogs combined with tamoxifen has become the standard treatment, although aromatase inhibitors plus ovarian function suppression are under evaluation. In postmenopausal patients, aromatase inhibitors have proved to be superior to standard endocrine therapies in either first- or second-line treatment and a novel antiestrogen compound, fulvestrant, has been introduced in clinical practice.

Chemotherapy remains the treatment of choice for hormone unresponsive or resistant patients. Anthracyclines and taxanes have been used either alone or in combination as first-line chemotherapy, but with the more frequent use of these agents in the adjuvant setting, new standards are needed for first-line chemotherapy, and new and more efficacious treatments are required.

In the subgroup of patients with tumors that overexpress HER-2, the use of trastuzumab alone or in combination with chemotherapy has modified the natural history of these tumors, even if only about one out of two patients obtains a clinical response.

In this review we summarize the main achievements and the currently available treatment options for patients with MBC.

Disclosure of potential conflicts of interest is found at the end of this article.

This article has been cited by other articles:

				J. Schwartz Current combination chemotherapy regimens for metastatic breast cancer Am. J. Health Syst. Pharm., December 1, 2009; 66(23_Supplement_6): S3 - S8. [Abstract] [Full Text] [PDF]

				L. Boehnke Michaud The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer Journal of Oncology Pharmacy Practice, June 1, 2009; 15(2): 95 - 106. [Abstract] [PDF]

				F. Cardoso, M. Castiglione, and On behalf of the ESMO Guidelines Working Group Locally recurrent or metastatic breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv15 - iv18. [Full Text] [PDF]

				S. Goodin Ixabepilone: A novel microtubule-stabilizing agent for the treatment of metastatic breast cancer Am. J. Health Syst. Pharm., November 1, 2008; 65(21): 2017 - 2026. [Abstract] [Full Text] [PDF]